KEY POINTS
- This retrospective single-center study compared two sequential prostate SABR planning pathways at the Northern Centre for Cancer Care in Newcastle, UK. The reported cohorts comprised 222 patients treated with MR-only planning between October 2024 and August 2025 and 262 treated using MR-CT fusion between January and October 2024. Both groups included favorable and unfavorable intermediate-risk prostate cancer, with approximately 36–37% receiving androgen deprivation therapy.
- All patients received prostate SABR using two-arc VMAT with 40 Gy in five fractions prescribed to the prostate CTV and 36.25 Gy in five fractions to the corresponding PTV. Unfavorable-risk patients received additional seminal vesicle coverage to 30 Gy in five fractions. Both pathways used comparable contouring guidance, target margins and daily CBCT verification; the main difference was the replacement of planning CT with MRI-derived synthetic CT for optimization and dose calculation.
- Median prostate target volume was numerically smaller with MR-only planning: 38 cm³ versus 40 cm³ using MR-CT fusion, representing approximately 4% reduction, but the overall difference was not statistically significant (p=0.07). Among unfavorable intermediate-risk patients, median prostate CTV volume decreased from 33 to 30 cm³ (approximately 10%; p=0.04), with a similar reduction in the extended seminal vesicle CTV (36 to 32 cm³; p=0.02).
- The strongest dosimetric difference involved the penile bulb, where median mean dose decreased by 52%, from 4.6 Gy with MR-CT fusion to 2.2 Gy with MR-only planning (p<0.001). This reduction was observed in both risk groups and may reflect more accurate visualization of the prostate apex and inferior target boundary. In contrast, no significant differences were identified in the evaluated bladder or rectal dose constraints.
- At the two-week acute toxicity assessment, grade ≥2 genitourinary toxicity was reported in 19.3% of MR-only patients versus 39.4% with MR-CT fusion, an absolute difference of −20.1 percentage points (95% CI −29.4 to −10.7). However, a major confounder was identified: when MR-only planning was introduced, the institution also stopped routinely offering SABR to patients with pre-existing lower urinary tract symptoms. Baseline toxicity data were unavailable, making it inappropriate to attribute the observed GU improvement to MR-only planning.
- Reported grade ≥2 sexual toxicity was 52.0% with MR-only planning versus 73.7% with MR-CT fusion, corresponding to an absolute difference of −21.7 percentage points (95% CI −39.7 to −3.7). This comparison was based on only 75 MR-only and 38 MR-CT respondents, representing approximately 34% and 14% of their respective cohorts. The low response rates, potential selection bias and influence of hormone therapy mean that the apparent sexual-toxicity benefit remains uncertain despite the significant penile bulb dose reduction.
- Acute gastrointestinal toxicity was similar, with grade ≥2 GI events in 4.1% versus 7.5% and a confidence interval compatible with no difference. The study measured toxicity only two weeks after treatment, without long-term erectile function, GU toxicity or oncological outcome data. Furthermore, the nonrandomized before-and-after design cannot separate the effects of MRI-only planning from institutional changes in patient selection, workflow or supportive care.
CLINICAL TAKEAWAY
MR-only planning for prostate SABR appears capable of substantially reducing penile bulb dose while eliminating a separate CT simulation and MRI-to-CT registration step. Although acute urinary and sexual toxicity rates were lower in the MR-only cohort, concurrent changes in eligibility criteria and incomplete baseline and follow-up data prevent these differences from being attributed to the imaging pathway; prospective evaluation of long-term outcomes is warranted.